Diabetes Mellitus, Type 2 Clinical Trial
— FAME-DOfficial title:
Food is Medicine: A Randomized Clinical Trial of Medically Tailored Meals For Individuals With Type 2 Diabetes Mellitus and Food Insecurity
The investigators propose a single-site, open-label, Phase II, community-based randomized clinical explanatory trial to test the efficacy of a medically tailored meal (MTM) interventions for adults with food insecurity and T2DM (Type 2 Diabetes Mellitus). While the efficacy of MTM needs to be established, given the nature of the population served by MTM, it is important to design the study to enhance the external validity/generalizability of the findings as much as possible. The investigators will recruit 200 participants from the referral list of Community Servings, a Boston-based MTM provider, and randomly assign them to MTM (N=100) or usual care + monthly food subsidy (N=100). MTM intervention will consist of 6 months of weekly delivery of 10 ready-to-eat meals (approximately half an individual's weekly food intake), along with telephone-based lifestyle intervention that prepares participants for the post-treatment period. The usual care + food subsidy recipients will receive usual care along with 6 months of a $40/month food subsidy.
| Status | Recruiting |
| Enrollment | 200 |
| Est. completion date | January 2026 |
| Est. primary completion date | August 2025 |
| Accepts healthy volunteers | No |
| Gender | All |
| Age group | 18 Years and older |
| Eligibility | Inclusion Criteria: - Diagnosis of Type 2 Diabetes Mellitus - Hemoglobin A1c = 7.0% and = 12.0% in last 12 months - Experiencing food insecurity as indicated by 2-item Hunger Vital Sign - English speaking - BMI =25 kg/m^2 (= 23 kg/m^2 if self-report Asian ancestry) - No plans to move from the area for at least 1 year - Free living to the extent that participant has control over dietary intake - Willing and able to provide written informed consent and participate in all study activities Exclusion Criteria: - Participant in diabetes, nutrition, or weight research intervention in last 12 months - Another family member or household member is a study participant. Only one member of each household may take part in this study. - Considering bariatric surgery in the next year or prior bariatric surgery in the past 2 years - Lack of safe, stable residence and ability to store meals - Lack of telephone - Pregnancy/breastfeeding or intended pregnancy in the next year - History of malignancy, other than non-melanoma skin cancer, unless surgically or medically cured > 5 years ago or in remission. Patients with localized prostate and breast cancer diagnosed during the course of routine screening will not be excluded. - Advanced kidney disease (estimated creatinine clearance < 30 mL/min) - Known drug or alcohol misuse in the past 2 years - Known psychosis or major psychiatric illness that prevents participation with study activities - Intermittent use of medications (e.g., oral or intravenous glucocorticoids) that are likely to affect blood sugar |
| Country | Name | City | State |
|---|---|---|---|
| United States | University of North Carolina at Chapel Hill | Chapel Hill | North Carolina |
| Lead Sponsor | Collaborator |
|---|---|
| University of North Carolina, Chapel Hill | Community Servings, Massachusetts General Hospital, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) |
United States,
| Type | Measure | Description | Time frame | Safety issue |
|---|---|---|---|---|
| Other | Bodyweight at Month 6 | Bodyweight measured in Kg | 6 months | |
| Other | Bodyweight at Month 12 | Bodyweight measured in Kg | 12 months | |
| Other | Systolic Blood Pressure at Month 6 | Systolic blood pressure in mm Hg | 6 months | |
| Other | Systolic Blood Pressure at Month 12 | Systolic blood pressure in mm Hg | 12 months | |
| Other | Diastolic Blood Pressure at Month 6 | Diastolic blood pressure measured in mm Hg | 6 months | |
| Other | Diastolic Blood Pressure at Month 12 | Diastolic blood pressure in mm Hg | 12 months | |
| Other | Diet Quality Score at Month 6 | Diet Quality as assessed by Brief Dietary Assessment Scale. This score is comprised of 3 sections (or subscales) used to assess dietary patterns. Subscales are scored independently. The subscales are: Vegetables, Fruit, Whole Grains, and Beans subscale (range 0 - 20), Drinks, Desserts, Snacks, Eating Out, and Salt subscale (range 0- 20), and Fish, Meat, Poultry, Dairy, and Eggs subscale (range 0-10): Total score equals the sum of the 3 subscales. For subscales and total score, higher scores indicates better diet quality. | 6 months | |
| Other | Diet Quality Score at Month 12 | Diet Quality as assessed by Brief Dietary Assessment Scale. This score is comprised of 3 sections (or subscales) used to assess dietary patterns. Subscales are scored independently. The subscales are: Vegetables, Fruit, Whole Grains, and Beans subscale (range 0 - 20), Drinks, Desserts, Snacks, Eating Out, and Salt subscale (range 0- 20), and Fish, Meat, Poultry, Dairy, and Eggs subscale (range 0-10): Total score equals the sum of the 3 subscales. For subscales and total score, higher scores indicates better diet quality. | 12 months | |
| Other | Cost-Related Medication Underuse at Month 6 | Any affirmative response to cost-related medication underuse items | 6 months | |
| Other | Cost-Related Medication Underuse at Month 12 | Any affirmative response to cost-related medication underuse items | 12 months | |
| Other | ARMS-D (Adherence to Refills and Medications Scale-Diabetes) Medication Adherence Score at Month 6 | Medication Adherence as assessed by 7-item ARMS-D scale. Scores range from 7 to 28, with higher scores indicating more problems with adherence. | 6 months | |
| Other | ARMS-D Medication Adherence Score at Month 12 | Medication Adherence as assessed by 7-item ARMS-D scale. Scores range from 7 to 28, with higher scores indicating more problems with adherence. | 12 months | |
| Other | Diabetes Self-Care Activities Medication Adherence Score at Month 6 | Medication Adherence as assessed by 1-item summary of diabetes self-care activities measure. Scores range from 0-7 with higher scores indicating better adherence. | 6 months | |
| Other | Diabetes Self-Care Activities Medication Adherence Score at Month 12 | Medication Adherence as assessed by 1-item summary of diabetes self-care activities measure. Scores range from 0-7 with higher scores indicating better adherence. | 12 months | |
| Other | Food/Medication Trade-offs at Month 6 | Single item-indicators of trading off medication for food or food for medication. An affirmative response indicates the presence of a trade-off. | 6 months | |
| Other | Food/Medication Trade-offs at Month 12 | Single item-indicators of trading off medication for food or food for medication. An affirmative response indicates the presence of a trade-off. | 12 months | |
| Other | Housing Insecurity at Month 6 | Self-report of being worried about losing housing | 6 months | |
| Other | Housing Insecurity Score at Month 12 | Self-report of being worried about losing housing | 12 months | |
| Other | Transportation Barriers at Month 6 | Self-report of transportation barriers to attending medical appointments | 6 months | |
| Other | Transportation Barriers at Month 12 | Self-report of transportation barriers to attending medical appointments | 12 months | |
| Other | Financial Strain | Self-report of financial strain | 6 months | |
| Other | Financial Strain | Self-report of financial strain | 12 months | |
| Other | Care Delay at Month 6 | Self-report of delaying healthcare due to cost | 6 months | |
| Other | Care Delay at Month 12 | Self-report of delaying healthcare due to cost | 12 months | |
| Other | Diet Self-Efficacy Score at Month 6 | Diet Self-Efficacy as assessed by cardiac diet self-efficacy scale. Scores range from 16 to 80 with higher scores indicating greater self-efficacy. | 6 months | |
| Other | Diet Self-Efficacy Score at Month 12 | Diet Self-Efficacy as assessed by cardiac diet self-efficacy scale. Scores range from 16 to 80 with higher scores indicating greater self-efficacy. | 12 months | |
| Other | Perceived Diabetes Self-Management Self-Efficacy Score at Month 6 | Diabetes Self-Efficacy as assessed by Perceived Diabetes Self-Management Scale. Scores range from 8 to 40 with higher scores indicating greater self-efficacy | 6 months | |
| Other | Perceived Diabetes Self-Management Self-Efficacy Score at Month 12 | Diabetes Self-Efficacy as assessed by Perceived Diabetes Self-Management Scale. Scores range from 8 to 40 with higher scores indicating greater self-efficacy | 12 months | |
| Other | Stress Score at 6 months | Stress as assessed by perceived stress scale. Scores range from 0 to 40 with higher scores indicating higher perceived stress. | 6 months | |
| Other | Stress Score at 12 months | Stress as assessed by perceived stress scale. Scores range from 0 to 40 with higher scores indicating higher perceived stress. | 12 months | |
| Primary | Hemoglobin A1c at Month 6 | Hemoglobin A1c Level | 6 months | |
| Secondary | Hemoglobin A1c at Month 12 | Hemoglobin A1c Level | 12 months | |
| Secondary | Food Insecurity Score at Month 6 | Food Insecurity Score. Score ranges from 0-10, with higher scores indicating greater food insecurity. | 6 months | |
| Secondary | Food Insecurity Score at Month 12 | Food Insecurity Score. Score ranges from 0-10, with higher scores indicating greater food insecurity. | 12 months | |
| Secondary | Health-Related Quality of Life Score as assessed by PROMIS (Patient-Reported Outcomes Measurement Information System)-29 at Month 6 | The PROMIS-29 includes seven health related quality of life domains (Physical Functioning, Anxiety, Depression, Fatigue, Sleep Disturbance, Social Functioning, and Pain), and the pain domain has two subdomains (interference and intensity). Raw scores, except pain intensity, are transformed using the T-score metric based on the item response theory calibrations in which scores have a mean of 50 and standard deviation of 10 for the general population in the US. A higher PROMIS T-score implies more of the concept being measured; i.e., a higher PROMIS score on physical function indicates better functioning, whereas a higher score on depression indicates more severe depressive symptoms. Will report overall score and scores for each domain. From these data we will also calculate a PROMIS-Preference (PROPr score) (PROPr scores range from -0.022 (worst) to 1.0 (best)). | 6 months | |
| Secondary | Health-Related Quality of Life Score as assessed by PROMIS-29 at Month 12 | The PROMIS-29 includes seven health related quality of life domains (Physical Functioning, Anxiety, Depression, Fatigue, Sleep Disturbance, Social Functioning, and Pain), and the pain domain has two subdomains (interference and intensity). Raw scores, except pain intensity, are transformed using the T-score metric based on the item response theory calibrations in which scores have a mean of 50 and standard deviation of 10 for the general population in the US. A higher PROMIS T-score implies more of the concept being measured; i.e., a higher PROMIS score on physical function indicates better functioning, whereas a higher score on depression indicates more severe depressive symptoms. Will report overall score and scores for each domain. From these data we will also calculate a PROMIS-Preference (PROPr score) (PROPr scores range from -0.022 (worst) to 1.0 (best)). | 12 months | |
| Secondary | Diabetes Distress Score as assessed by PAID (Problem Areas in Diabetes)-11 at Month 6 | Score ranges from 11-55 with higher scores indicating greater diabetes distress | 6 months | |
| Secondary | Diabetes Distress Score as assessed by PAID-11 at Month 12 | Score ranges from 11-55 with higher scores indicating greater diabetes distress | 12 months | |
| Secondary | Depressive Symptom Score at Month 6 | Depressive Symptoms as assessed by PROMIS SF (Short Form) v1.0 - Depression 4a. Raw scores are transformed using the T-score metric based on the item response theory calibrations in which scores have a mean of 50 and standard deviation of 10 for the general population in the US. A higher PROMIS T-score implies more of the concept being measured; i.e., a higher PROMIS score on depression indicates more severe depressive symptoms. | 6 months | |
| Secondary | Depressive Symptom Score at Month 12 | Depressive Symptoms as assessed by PROMIS SF v1.0 - Depression 4a. Raw scores are transformed using the T-score metric based on the item response theory calibrations in which scores have a mean of 50 and standard deviation of 10 for the general population in the US. A higher PROMIS T-score implies more of the concept being measured; i.e., a higher PROMIS score on depression indicates more severe depressive symptoms. | 12 months | |
| Secondary | Frequency of self-reported hypoglycemia at Month 6 | Categorized by number of episodes on prior 3 months | 6 months | |
| Secondary | Frequency of self-reported hypoglycemia at Month 12 | Categorized by number of episodes on prior 3 months | 12 months | |
| Secondary | Frequency of self-reported severe hypoglycemia at Month 6 | Categorized by number of episodes on prior 3 months | 6 months | |
| Secondary | Frequency of self-reported severe hypoglycemia at Month 12 | Categorized by number of episodes on prior 3 months | 12 months |
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Active, not recruiting |
NCT05666479 -
CGM Monitoring in T2DM Patients Undergoing Orthopaedic Replacement Surgery
|
||
| Completed |
NCT05647083 -
The Effect of Massage on Diabetic Parameters
|
N/A | |
| Active, not recruiting |
NCT05661799 -
Persistence of Physical Activity in People With Type 2 Diabetes Over Time.
|
N/A | |
| Completed |
NCT03686722 -
Effect of Co-administration of Metformin and Daclatasvir on the Pharmacokinetis and Pharmacodynamics of Metformin
|
Phase 1 | |
| Completed |
NCT02836704 -
Comparison of Standard vs Higher Starting Dose of Insulin Glargine in Chinese Patients With Type 2 Diabetes (Glargine Starting Dose)
|
Phase 4 | |
| Completed |
NCT01819129 -
Efficacy and Safety of FIAsp Compared to Insulin Aspart in Combination With Insulin Glargine and Metformin in Adults With Type 2 Diabetes
|
Phase 3 | |
| Completed |
NCT04562714 -
Impact of Flash Glucose Monitoring in People With Type 2 Diabetes Using Non-Insulin Antihyperglycemic Therapy
|
N/A | |
| Completed |
NCT02009488 -
Treatment Differences Between Canagliflozin and Placebo in Insulin Secretion in Subjects With Type 2 Diabetes Mellitus (T2DM)
|
Phase 1 | |
| Completed |
NCT05896319 -
Hyaluronic Acid Treatment of the Post-extraction Tooth Socket Healing in Subjects With Diabetes Mellitus Type 2
|
N/A | |
| Recruiting |
NCT05598203 -
Effect of Nutrition Education Groups in the Treatment of Patients With Type 2 Diabetes
|
N/A | |
| Completed |
NCT05046873 -
A Research Study Looking Into Blood Levels of Semaglutide and NNC0480-0389 When Given in the Same Injection or in Two Separate Injections in Healthy People
|
Phase 1 | |
| Terminated |
NCT04090242 -
Impact of App Based Diabetes Training Program in Conjunction With the BD Nano Pen Needle in People With T2 Diabetes
|
N/A | |
| Completed |
NCT04030091 -
Pulsatile Insulin Infusion Therapy in Patients With Type 1 and Type 2 Diabetes Mellitus
|
Phase 4 | |
| Completed |
NCT03604224 -
A Study to Observe Clinical Effectiveness of Canagliflozin 300 mg Containing Treatment Regimens in Indian Type 2 Diabetes Participants With BMI>25 kg/m^2, in Real World Clinical Setting
|
||
| Completed |
NCT03620357 -
Continuous Glucose Monitoring & Management In Type 2 Diabetes (T2D)
|
N/A | |
| Completed |
NCT01696266 -
An International Survey on Hypoglycaemia Among Insulin-treated Patients With Diabetes
|
||
| Completed |
NCT03620890 -
Detemir Versus NPH for Type 2 Diabetes Mellitus in Pregnancy
|
Phase 4 | |
| Withdrawn |
NCT05473286 -
A Research Study Looking at How Oral Semaglutide Works in People With Type 2 Diabetes in Germany, as Part of Local Clinical Practice
|
||
| Not yet recruiting |
NCT05029804 -
Effect of Walking Exercise Training on Adherence to Disease Management and Metabolic Control in Diabetes
|
N/A | |
| Completed |
NCT04531631 -
Effects of Dorzagliatin on 1st Phase Insulin and Beta-cell Glucose Sensitivity in T2D and Monogenic Diabetes
|
Phase 2 |